IMIPRAMINE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H24N2.ClH
Molecular Weight	316.868
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CN(C)CCCN1C2=C(CCC3=C1C=CC=C3)C=CC=C2

InChI

InChIKey=XZZXIYZZBJDEEP-UHFFFAOYSA-N

InChI=1S/C19H24N2.ClH/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21;/h3-6,8-11H,7,12-15H2,1-2H3;1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C19H24N2
Molecular Weight	280.4073
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugbank.ca/drugs/DB00458
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/087846s028,087844s027,087845s027lbl.pdf

Imipramine is a tricyclic antidepressant with general pharmacological properties similar to those of structurally related tricyclic antidepressant drugs such as amitriptyline and doxepin. A tertiary amine, imipramine inhibits the reuptake of serotonin more so than most secondary amine tricyclics, meaning that it blocks the reuptake of neurotransmitters serotonin and noradrenaline almost equally. With chronic use, imipramine also down-regulates cerebral cortical β-adrenergic receptors and sensitizes post-synaptic sertonergic receptors, which also contributes to increased serotonergic transmission. It takes approximately 2 - 4 weeks for antidepressants effects to occur. The onset of action may be longer, up to 8 weeks, in some individuals. It is also effective in migraine prophylaxis, but not in abortion of acute migraine attack. Imipramine works by inhibiting the neuronal reuptake of the neurotransmitters norepinephrine and serotonin. It binds the sodium-dependent serotonin transporter and sodium-dependent norepinephrine transporter preventing or reducing the reuptake of norepinephrine and serotonin by nerve cells. Depression has been linked to a lack of stimulation of the post-synaptic neuron by norepinephrine and serotonin. Slowing the reuptake of these neurotransmitters increases their concentration in the synaptic cleft, which is thought to contribute to relieving symptoms of depression. In addition to acutely inhibiting neurotransmitter re-uptake, imipramine causes down-regulation of cerebral cortical beta-adrenergic receptors and sensitization of post-synaptic serotonergic receptors with chronic use. This leads to enhanced serotonergic transmission. Used for relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older. May also be used to manage panic disorders, with or without agoraphobia, as a second line agent in ADHD, management of eating disorders, for short-term management of acute depressive episodes in bipolar disorder and schizophrenia, and for symptomatic treatment of postherpetic neuralgia.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Serum paraoxonase/arylesterase 1 31 Target ID: P27169 Gene ID: 5444.0 Gene Symbol: PON1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/23001316	Inhibitor 8228
Norepinephrine transporter 190 Target ID: CHEMBL222 Sources: https://www.drugbank.ca/drugs/DB00458	Inhibitor 8228	12.0 nM [Ki]
Serotonin transporter 177 Target ID: CHEMBL228 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18983139	Inhibitor 8228	3.2 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Depression 233 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/087846s028,087844s027,087845s027lbl.pdf	Primary		Approved 8360	Tofranil Approved Use Tofranil is used for: Treating depression. It is also used in some children to help reduce bedwetting. It may also be used for other conditions as determined by your doctor. Launch Date 4.5394559E11

C_max

Value	Dose	Co-administered	Analyte	Population
107 μg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/2185906/	130 mg 1 times / day steady-state, oral dose: 130 mg route of administration: Oral experiment type: STEADY-STATE co-administered: Desipramine	Desipramine	IMIPRAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
24.5 ng/mL OTHER https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/S0009-9236%2897%2990062-X	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		IMIPRAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
427 ng × h/mL OTHER https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/S0009-9236%2897%2990062-X	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		IMIPRAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
12 h REVIEW https://pubmed.ncbi.nlm.nih.gov/2185906/	130 mg 1 times / day steady-state, oral dose: 130 mg route of administration: Oral experiment type: STEADY-STATE co-administered: Desipramine	Desipramine	IMIPRAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
21.1 h OTHER https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/S0009-9236%2897%2990062-X	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		IMIPRAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
22% REVIEW https://pubmed.ncbi.nlm.nih.gov/2185906/	130 mg 1 times / day steady-state, oral dose: 130 mg route of administration: Oral experiment type: STEADY-STATE co-administered: Desipramine	Desipramine	IMIPRAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
200 mg/day 1 times / day steady, oral Dose: 200 mg/day, 1 times / day Route: oral Route: steady Dose: 200 mg/day, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9023787	unhealthy, 18-70 years n = 82 Health Status: unhealthy Condition: major depression \| melancholia Age Group: 18-70 years Population Size: 82 Sources: https://pubmed.ncbi.nlm.nih.gov/9023787	Disc. AE: Nausea... AEs leading to discontinuation/dose reduction: Nausea (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/9023787
25 mg/day 1 times / day steady, oral Dose: 25 mg/day, 1 times / day Route: oral Route: steady Dose: 25 mg/day, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19653341	unhealthy, 42.6 ± 12.4 years n = 59 Health Status: unhealthy Condition: irritable bowel syndrome Age Group: 42.6 ± 12.4 years Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/19653341	Disc. AE: Sleep disturbance, Urinary tract signs and symptoms NEC... AEs leading to discontinuation/dose reduction: Sleep disturbance (3 patients) Urinary tract signs and symptoms NEC (2 patients) Palpitations (2 patients) Anxiety (1 patient) Dry mouth (1 patient) Dizziness (3 patients) Flushing (1 patient) Constipation (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/19653341
75 mg/day 1 times / day steady, oral (starting) Recommended Dose: 75 mg/day, 1 times / day Route: oral Route: steady Dose: 75 mg/day, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017090s078lbl.pdf	unhealthy, < 24 years Health Status: unhealthy Condition: depression Age Group: < 24 years Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017090s078lbl.pdf	Disc. AE: Suicidal ideation... AEs leading to discontinuation/dose reduction: Suicidal ideation (grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017090s078lbl.pdf

AEs

AE	Significance	Dose	Population
Nausea	1 patient Disc. AE	200 mg/day 1 times / day steady, oral Dose: 200 mg/day, 1 times / day Route: oral Route: steady Dose: 200 mg/day, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9023787	unhealthy, 18-70 years n = 82 Health Status: unhealthy Condition: major depression \| melancholia Age Group: 18-70 years Population Size: 82 Sources: https://pubmed.ncbi.nlm.nih.gov/9023787
Anxiety	1 patient Disc. AE	25 mg/day 1 times / day steady, oral Dose: 25 mg/day, 1 times / day Route: oral Route: steady Dose: 25 mg/day, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19653341	unhealthy, 42.6 ± 12.4 years n = 59 Health Status: unhealthy Condition: irritable bowel syndrome Age Group: 42.6 ± 12.4 years Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/19653341
Constipation	1 patient Disc. AE	25 mg/day 1 times / day steady, oral Dose: 25 mg/day, 1 times / day Route: oral Route: steady Dose: 25 mg/day, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19653341	unhealthy, 42.6 ± 12.4 years n = 59 Health Status: unhealthy Condition: irritable bowel syndrome Age Group: 42.6 ± 12.4 years Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/19653341
Dry mouth	1 patient Disc. AE	25 mg/day 1 times / day steady, oral Dose: 25 mg/day, 1 times / day Route: oral Route: steady Dose: 25 mg/day, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19653341	unhealthy, 42.6 ± 12.4 years n = 59 Health Status: unhealthy Condition: irritable bowel syndrome Age Group: 42.6 ± 12.4 years Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/19653341
Flushing	1 patient Disc. AE	25 mg/day 1 times / day steady, oral Dose: 25 mg/day, 1 times / day Route: oral Route: steady Dose: 25 mg/day, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19653341	unhealthy, 42.6 ± 12.4 years n = 59 Health Status: unhealthy Condition: irritable bowel syndrome Age Group: 42.6 ± 12.4 years Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/19653341
Palpitations	2 patients Disc. AE	25 mg/day 1 times / day steady, oral Dose: 25 mg/day, 1 times / day Route: oral Route: steady Dose: 25 mg/day, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19653341	unhealthy, 42.6 ± 12.4 years n = 59 Health Status: unhealthy Condition: irritable bowel syndrome Age Group: 42.6 ± 12.4 years Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/19653341
Urinary tract signs and symptoms NEC	2 patients Disc. AE	25 mg/day 1 times / day steady, oral Dose: 25 mg/day, 1 times / day Route: oral Route: steady Dose: 25 mg/day, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19653341	unhealthy, 42.6 ± 12.4 years n = 59 Health Status: unhealthy Condition: irritable bowel syndrome Age Group: 42.6 ± 12.4 years Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/19653341
Dizziness	3 patients Disc. AE	25 mg/day 1 times / day steady, oral Dose: 25 mg/day, 1 times / day Route: oral Route: steady Dose: 25 mg/day, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19653341	unhealthy, 42.6 ± 12.4 years n = 59 Health Status: unhealthy Condition: irritable bowel syndrome Age Group: 42.6 ± 12.4 years Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/19653341
Sleep disturbance	3 patients Disc. AE	25 mg/day 1 times / day steady, oral Dose: 25 mg/day, 1 times / day Route: oral Route: steady Dose: 25 mg/day, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19653341	unhealthy, 42.6 ± 12.4 years n = 59 Health Status: unhealthy Condition: irritable bowel syndrome Age Group: 42.6 ± 12.4 years Sex: M+F Population Size: 59 Sources: https://pubmed.ncbi.nlm.nih.gov/19653341
Suicidal ideation	grade 5 Disc. AE	75 mg/day 1 times / day steady, oral (starting) Recommended Dose: 75 mg/day, 1 times / day Route: oral Route: steady Dose: 75 mg/day, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017090s078lbl.pdf	unhealthy, < 24 years Health Status: unhealthy Condition: depression Age Group: < 24 years Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017090s078lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1709		substrate 1193	inhibitor 1599

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT2 638 OCT3 149 MATE1 304 MATE2 261	CYP2C19 985 CYP1A2 1032 P-gp 1527 UGT2B10 127 UGT1A4 347 UGT1A3 422

Drug as perpetrator

Target	Modality	Activity
OCT2 639	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/19002438/	yes [IC50 6 uM]
MATE2 261	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/19164462/	yes [Ki 182.9 uM]
MATE1 306	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/19164462/	yes [Ki 42 uM]
OCT3 149	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/10966924/	yes [Ki 42 uM]

Drug as victim

Target	Modality	Activity
CYP1A2 1032	substrate 3326 Sources: https://academic.oup.com/jat/article/38/6/368/2797982	yes
CYP2C19 985	substrate 3326 Sources: https://academic.oup.com/jat/article/38/6/368/2797982	yes
CYP2D6 1193	substrate 3326 Sources: https://academic.oup.com/jat/article/38/6/368/2797982	yes
CYP3A4 1709	substrate 3326 Sources: https://academic.oup.com/jat/article/38/6/368/2797982	yes
P-gp 1527	substrate 3326 Sources: https://academic.oup.com/ijnp/article/16/10/2259/653065	yes
UGT1A3 422	substrate 3326 Sources: https://sci-hub.do/10.1124/dmd.109.030981	yes
UGT1A4 347	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/20133892/	yes
UGT2B10 127	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/20133892/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1632	inhibitor 1613 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1571643/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:47499	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:47499
ChemicalBook	CB1727489	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1727489
MolPort	MolPort-001-783-692	https://www.molport.com/shop/molecule-link/MolPort-001-783-692
ZINC	ZINC000000020245	http://zinc15.docking.org/substances/ZINC000000020245

PubMed

Title	Date	PubMed
The antinicotinic effects of drugs with clinically useful sedative-antianxiety properties.	1975	1803
Cardiac arrhythmia and imipramine therapy.	1975 Mar 22	1125654
Imipramine-induced heart block. A longitudinal case study.	1975 Mar 31	1173081
Imipramine dosage in children: a comment on "imipramine and electrocardiographic abnormalities in hyperactive children".	1975 May	1119617
Imipramine and electrocardiographic abnormalities in hyperactive children.	1975 May	1119616
[Behavior pharmacology of maprotiline, a new antidepressant].	1975 Nov	1240830
Letter: Imipramine-induced heart block.	1975 Oct 27	1174365
Imipramine toxicity.	1975 Sep	1142523
Pediatric cardiovascular effects of imipramine and desipramine.	1991 Jan	2005043
Rabbit syndrome, antidepressant use, and cerebral perfusion SPECT scan findings.	1991 Nov	1786266
[Clinical-pharmacological case report: drug-induced inappropriate ADH secretion].	1992 Nov 17	1448636
Gabapentin therapy for cocaine cravings.	2000 Dec	11097986
Sudden death of a child treated with imipramine. Case study.	2000 Winter	11191693
The use of short-form quality of life questionnaires to measure the impact of imipramine on women with urge incontinence.	2001	11715997
Induction of cysteine string protein after chronic antidepressant treatment in rat frontal cortex.	2001 Apr 6	11257428
Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial.	2001 Aug	11473503
Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2.	2001 Dec	11714871
[Depression in the elderly. Medical treatment].	2001 Feb 24	11262813
Relative bioavailability of imipramine (Tofranil) coated tablets in healthy volunteers.	2001 Jun	11430636
Pharmacokinetics of imipramine in narcoleptic horses.	2001 May	11341404
[Evaluation of analgesic action of fluvoxamine compared with efficacy of imipramine and tramadol for treatment of sciatica--open trial].	2002	12043315
Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine.	2002 Apr	11910263
Adverse pulmonary vascular effects of high dose tricyclic antidepressants: acute and chronic animal studies.	2002 Aug	12212966
Evaluation of the anti-inflammatory and anti-nociceptive effects of different antidepressants in the rat.	2003 Aug	12798668
Phenelzine treatment increases transcription factor AP-2 levels in rat brain.	2003 Aug 28	12943557
Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients.	2003 Feb 1	12586234
N-glucuronidation of nicotine and cotinine by human liver microsomes and heterologously expressed UDP-glucuronosyltransferases.	2003 Nov	14570768
Glutathione S-transferase pi as a target for tricyclic antidepressants in human brain.	2004	15094841
Long-term imipramine withdrawal induces a depressive-like behaviour in the forced swimming test.	2004 May 10	15145707
Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance.	2004 Nov	15286053
[Effect of acute melipramine administration on motor activity and defensive conditioned reflexes of passive and active avoidance in rats].	2004 Nov-Dec	15658049
Mechanism of block of hEag1 K+ channels by imipramine and astemizole.	2004 Oct	15365094
[Cardiac arrhythmia in amitriptyline poisoning in children].	2005 Apr-Jun	16607780
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005 Jun	15962942
Organophosphorothionate pesticides inhibit the bioactivation of imipramine by human hepatic cytochrome P450s.	2005 Jun 15	15922009
QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.	2005 Mar	15687478
Serotonin (5HT), fluoxetine, imipramine and dopamine target distinct 5HT receptor signaling to modulate Caenorhabditis elegans egg-laying behavior.	2005 Mar	15654117
UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation.	2005 May	15708967
[Lack of antidepresant-like activity of some ligands of polyamine binding sites of NMDA receptors in models of depression].	2006 Jan-Feb	16579050
Frequency of high-risk use of QT-prolonging medications.	2006 Jun	16178046
Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells.	2006 Mar 13	16324787
Influence of antidepressants on hemostasis.	2007	17506225
Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli.	2007 Nov 8	17988634
In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies.	2007 Sep	17567588
Temporal expression of brain-derived neurotrophic factor (BDNF) mRNA in the rat hippocampus after treatment with selective and mixed monoaminergic antidepressants.	2008 Jan 14	17950272
D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action.	2008 Jul 28	18561912
Pharmacological separation of hEAG and hERG K+ channel function in the human mammary carcinoma cell line MCF-7.	2008 Jun	18497958
Gene expression profiling in rat liver treated with compounds inducing phospholipidosis.	2008 Jun 15	18355885
Community-based randomised controlled trial evaluating falls and osteoporosis risk management strategies.	2008 Nov 4	18983670
Suppressive effect of imipramine on vincristine-induced mechanical allodynia in mice.	2009 Jul	19571391

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Depression Tablets: Initial dose: 100 mg orally per day Maintenance dose: 100 to 200 mg orally per day (If no response after 2 weeks, increase to 250 to 300 mg per day) Maximum dose: 300 mg orally per day

Route of Administration: Oral

In Vitro Use Guide

The inhibition percentage of human PON1 for imipramine was 15.6% at 100 ug/L after incubation for 1 h). At 350 ug/L, the inhibition percentage for imipramine 19.2% after 1 h and 20.2% after 2 h.

Substance Class	Chemical Created by `admin` on `Wed Jul 05 22:43:57 UTC 2023` Edited by `admin` on `Wed Jul 05 22:43:57 UTC 2023`
Record UNII	BKE5Q1J60U
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IMIPRAMINE HYDROCHLORIDE

Common Name

English

IMIPRAMINE HYDROCHLORIDE [USP-RS]

Common Name

English

IMIPRAMINE HYDROCHLORIDE [MI]

Common Name

English

IMIPRAMINE HYDROCHLORIDE [USP IMPURITY]

Common Name

English

IMIZINE

Common Name

English

IMIDOBENZYLE

Common Name

English

TOFRANIL

Common Name

English

Imipramine hydrochloride [WHO-DD]

Common Name

English

IMIPRAMINI HYDROCHLORIDUM [WHO-IP LATIN]

Common Name

English

IMIPRAMINE HYDROCHLORIDE [MART.]

Common Name

English

NSC-114900

Code

English

PRAMINE

Brand Name

English

PRYLEUGAN

Common Name

English

PRESAMINE

Brand Name

English

5-(3-(DIMETHYLAMINO)PROPYL)-10,11-DIHYDRO-5H-DIBENZ(B,F)AZEPINE MONOHYDROCHLORIDE

Systematic Name

English

IMIPRAMINE HCL

Common Name

English

JANIMINE

Brand Name

English

IMIPRAMINE HYDROCHLORIDE [USP MONOGRAPH]

Common Name

English

IMIPRAMINE HYDROCHLORIDE [VANDF]

Common Name

English

IMIPRAMINE HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

5H-DIBENZ(B,F)AZEPINE-5-PROPANAMINE, 10,11-DIHYDRO-N,N-DIMETHYL-, MONOHYDROCHLORIDE

Common Name

English

IMIPRAMINE HYDROCHLORIDE [JAN]

Common Name

English

IMIPRAMINE HYDROCHLORIDE [EP MONOGRAPH]

Common Name

English

G-22355

Code

English

IMIPRAMINE HYDROCHLORIDE [WHO-IP]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C94727